Investigational medicine
Retatrutide
An investigational agonist of GIP, GLP-1 and glucagon receptors.
Also discussed as: Reta · LY3437943 · Triple agonist
THE RESEARCH QUESTION
What is being investigated?
Lilly is studying retatrutide for obesity, type 2 diabetes and related conditions. Phase 3 results are available, including TRIUMPH-2 results announced in September 2026.
EVIDENCE SNAPSHOT
Phase 3 human trials
Phase 3 studies have reported weight and blood-glucose outcomes in specific patient groups. Results and announcements are not a marketing authorisation. Lilly still describes retatrutide as investigational and available only through its clinical trials.
LIMITS & SAFETY
What should you know?
Trial monitoring does not establish the quality or safety of products sold online as ‘reta’.
FOLLOW THE EVIDENCE
Sources & further reading
- Lilly: current retatrutide research and investigational status ↗Trial sponsor
- Lilly: TRIUMPH-2 phase 3 results (September 2026) ↗Trial sponsor results
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.